Pharma BD Deal Intelligence

Boehringer Ingelheim GmbH / AMAL Therapeutics SA

2019 · Acquisition/Merger · $366M · Complete

Announcement Sentiment

Strongly positive

Boehringer Ingelheim acquired AMAL Therapeutics for up to EUR 325M (EUR 225M upfront and development milestones plus EUR 100M commercial milestones; ~$366M), adding the KISIMA cancer vaccine platform with lead asset ATP128 in colorectal cancer.

Key facts

Announced Sep 09, 2019
Deal value $366M
Deal type Acquisition/Merger
Therapeutic area Colorectal cancer, solid tumors
Indications Colorectal cancer, solid tumors
Key assets KISIMA cancer vaccine platform (ATP128)
Mechanism Self-assembling protein cancer vaccine

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals